Integra LifeSciences (IART) Misses Q3 EPS by 2c; Lowers Outlook

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.45, $0.02 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $278.8 million versus the consensus estimate of $286.33 million.

GUIDANCE:

Integra LifeSciences sees FY2017 EPS of $1.83-$1.87, versus the consensus of $1.91.

The company is lowering its 2017 full-year organic sales growth to about 4%, from its previous guidance of 6.0% to 7.0%, reflecting the impact from storm-related disruptions and lower base business sales growth

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM